124 related articles for article (PubMed ID: 1306729)
1. Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia.
Toma S; Mangiante PE; Margarino G; Nicolo G; Palumbo R
Eur J Cancer B Oral Oncol; 1992 Oct; 28B(2):121-3. PubMed ID: 1306729
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity.
Dimery IW; Hong WK; Lee JJ; Guillory-Perez C; Pham F; Fritsche HA; Lippman SM
Ann Oncol; 1997 Jan; 8(1):85-9. PubMed ID: 9093712
[TBL] [Abstract][Full Text] [Related]
3. bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study.
Piattelli A; Fioroni M; Santinelli A; Rubini C
Oral Oncol; 1999 May; 35(3):314-20. PubMed ID: 10621853
[TBL] [Abstract][Full Text] [Related]
4. 13-cis-retinoic acid in the treatment of oral leukoplakia.
Hong WK; Endicott J; Itri LM; Doos W; Batsakis JG; Bell R; Fofonoff S; Byers R; Atkinson EN; Vaughan C
N Engl J Med; 1986 Dec; 315(24):1501-5. PubMed ID: 3537787
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.
Weisman RA; Christen R; Los G; Jones V; Kerber C; Seagren S; Glassmeyer S; Orloff LA; Wong W; Kirmani S; Howell S
Otolaryngol Head Neck Surg; 1998 May; 118(5):597-602. PubMed ID: 9591856
[TBL] [Abstract][Full Text] [Related]
6. Effect of retinoids on oral leukoplakia.
Shah JP; Strong EW; DeCosse JJ; Itri L; Sellers P
Am J Surg; 1983 Oct; 146(4):466-70. PubMed ID: 6578687
[TBL] [Abstract][Full Text] [Related]
7. The use of 13-cis-retinoic acid in the treatment of oral leukoplakia: short-term observations.
Kaugars G; Silverman S
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1995 Mar; 79(3):264-5. PubMed ID: 7620998
[No Abstract] [Full Text] [Related]
8. Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid.
Beenken SW; Sellers MT; Huang P; Peters G; Krontiras H; Dixon P; Stockard C; Listinsky C; Grizzle WE
Head Neck; 1999 Sep; 21(6):566-73. PubMed ID: 10449674
[TBL] [Abstract][Full Text] [Related]
9. The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin.
Tetè S; Pappalardo S; Rubini C; Salini L; Falco A; Perfetti EG
Minerva Stomatol; 1999 Sep; 48(9):411-8. PubMed ID: 10638174
[TBL] [Abstract][Full Text] [Related]
10. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
Recchia F; De Filippis S; Rosselli M; Saggio G; Cesta A; Fumagalli L; Rea S
Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feasibility study.
Ruotsalainen T; Halme M; Isokangas OP; Pyrhönen S; Mäntylä M; Pekonen M; Sarna S; Joensuu H; Mattson K
Anticancer Drugs; 2000 Feb; 11(2):101-8. PubMed ID: 10789592
[TBL] [Abstract][Full Text] [Related]
12. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis.
Lippman SM; Batsakis JG; Toth BB; Weber RS; Lee JJ; Martin JW; Hays GL; Goepfert H; Hong WK
N Engl J Med; 1993 Jan; 328(1):15-20. PubMed ID: 8416267
[TBL] [Abstract][Full Text] [Related]
13. Retinoid modulation of biomarkers in oral leukoplakia/dysplasia.
Beenken SW; Huang P; Sellers M; Peters G; Listinsky C; Stockard C; Hubbard W; Wheeler R; Grizzle W
J Cell Biochem Suppl; 1994; 19():270-7. PubMed ID: 7823600
[TBL] [Abstract][Full Text] [Related]
14. A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias. The Central Pennsylvania Oncology Group.
Besa EC; Kunselman S; Nowell PC
Leuk Res; 1998 Aug; 22(8):741-9. PubMed ID: 9680102
[TBL] [Abstract][Full Text] [Related]
15. Treatment of oral leukoplakia with beta-carotene.
Toma S; Benso S; Albanese E; Palumbo R; Cantoni E; Nicolò G; Mangiante P
Oncology; 1992; 49(2):77-81. PubMed ID: 1574255
[TBL] [Abstract][Full Text] [Related]
16. Results, toxicity and compliance in chemoprevention trials of head and neck cancer.
Toma S; Palumbo R; Rosso R
Eur J Cancer Prev; 1994 Jan; 3(1):63-8. PubMed ID: 8130719
[TBL] [Abstract][Full Text] [Related]
17. Current status of chemoprevention of head and neck cancer.
Benner SE; Lippman SM; Hong WK
Oncology (Williston Park); 1992 Aug; 6(8):61-6; discussion 66-8, 71 passim. PubMed ID: 1386997
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II study.
Recchia F; De Filippis S; Rosselli M; Saggio G; Fumagalli L; Rea S
Int J Oncol; 2002 Jun; 20(6):1275-82. PubMed ID: 12012010
[TBL] [Abstract][Full Text] [Related]
19. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
Tsimberidou AM; Giles F; Romaguera J; Duvic M; Kurzrock R
Cancer; 2004 Feb; 100(3):574-80. PubMed ID: 14745875
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
